Novel Lenses for Myopia Progression Trial
Key facts
- Who runs it
- Shanghai Eye Disease Prevention and Treatment Center
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 342 people enrolled
- Started
- 16 Aug 2024
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- spectacle lens
- single vision lens
- Record updated
- 28 April 2026
Who can take part
- Age
- 7 years to 13 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- be accompanied by a parent or guardian who is able to read and comprehend Chinese/English and sign a record of informed consent/assent; at baseline, be within the age range of 7 to 13 years old inclusive; be diagnosed as myopic having cycloplegic spherical equivalent between -0.75 dioptre (D) and -5.00 dioptre (D); astigmatism ≤1.50D; anisometropia of not more than 1.50D; be willing to comply with the wearing of clinical trial spectacles and clinical trial visit schedule as directed by the investigator; have ocular findings deemed to be normal; vision correctable to at least 0.8 or better in each eye with spectacles
Who cannot take part
- Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the clinical trial
- History of eye trauma Amblyopia Strabismus History of use of myopia control interventions such as Orthokeratology, atropine or eye surgery 6 months prior to commencement of this trial
- Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error; Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants
- Known allergy or intolerance to ingredients to cycloplegic eye-drops. Currently enrolled in another clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center , prospective, randomised, longitudinal study to evaluate rate of myopia progression with novel lenses compared to Single-Vision spectacles. A total of 342 children will be recruited where 57 participants each are randomised to wear one of 5 test spectacle lens designs or a single vision lens (control) for 12 months. At the end of 12 months, those randomised to single vision lenses will be transferred to one of the test lenses and all the groups continued for another 12 months. Myopia progression during the second year with test lenses will be compared to historical or published controls.
The 6 groups in the trial
- Group APlacebo, for comparison
single vision lens
Treatment: spectacle lens and single vision lens
- Group BTreatment being tested
one of ZEISS BD spectacle lens designs 1 to 5
Treatment: spectacle lens
- Group CTreatment being tested
one of ZEISS BD spectacle lens designs 1 to 5
Treatment: spectacle lens
- Group DTreatment being tested
one of ZEISS BD spectacle lens designs 1 to 5
Treatment: spectacle lens
- Group ETreatment being tested
one of ZEISS BD spectacle lens designs 1 to 5
Treatment: spectacle lens
- Group FTreatment being tested
one of ZEISS BD spectacle lens designs 1 to 5
Treatment: spectacle lens
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double Masked, Randomised, Longitudinal Comparative Study to Evaluate the Myopia Progression of Novel Spectacle Lenses Versus Single Vision Spectacle Lenses in Children With Myopia
- Record updated
- 28 April 2026